v3.25.2
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Millions
Common Stock
Treasury Stock at Cost
Additional Paid-in Capital
Retained Earnings (Accumulated Deficit)
Total
Balances at beginning of period at Dec. 31, 2023 $ 1.0 $ (154.9) $ 391.8 $ 20.3 $ 258.2
Balances at beginning of period (in shares) at Dec. 31, 2023 83,557,786        
Increase (Decrease) in Stockholders' Deficit          
Stock-based compensation     3.0   3.0
Issuance of restricted stock, net (in shares) 111,431        
Purchase of shares   (1.6)     (1.6)
Purchase of shares (in shares) (339,891)        
Net Income (Loss)       (15.0) (15.0)
Balances at end of period at Mar. 31, 2024 [1] $ 1.0 (156.5) 394.8 5.3 244.6
Balances at end of period (in shares) at Mar. 31, 2024 [1] 83,329,326        
Balances at beginning of period at Dec. 31, 2023 $ 1.0 (154.9) 391.8 20.3 258.2
Balances at beginning of period (in shares) at Dec. 31, 2023 83,557,786        
Increase (Decrease) in Stockholders' Deficit          
Net Income (Loss)         (25.8)
Balances at end of period at Jun. 30, 2024 [1] $ 1.0 (156.6) 397.7 (5.5) 236.6
Balances at end of period (in shares) at Jun. 30, 2024 [1] 84,757,140        
Balances at beginning of period at Mar. 31, 2024 [1] $ 1.0 (156.5) 394.8 5.3 244.6
Balances at beginning of period (in shares) at Mar. 31, 2024 [1] 83,329,326        
Increase (Decrease) in Stockholders' Deficit          
Stock-based compensation     2.9   2.9
Issuance of restricted stock, net (in shares) 1,449,131        
Purchase of shares   (0.1)     (0.1)
Purchase of shares (in shares) (21,317)        
Net Income (Loss)       (10.8) (10.8)
Balances at end of period at Jun. 30, 2024 [1] $ 1.0 (156.6) 397.7 (5.5) 236.6
Balances at end of period (in shares) at Jun. 30, 2024 [1] 84,757,140        
Balances at beginning of period at Dec. 31, 2024 $ 1.0 (156.6) 402.9 (38.5) $ 208.8
Balances at beginning of period (in shares) at Dec. 31, 2024 84,810,418       84,810,418
Increase (Decrease) in Stockholders' Deficit          
Stock-based compensation     2.4   $ 2.4
Issuance of restricted stock, net (in shares) 1,029,789        
Purchase of shares   (1.3)     (1.3)
Purchase of shares (in shares) (252,322)        
Net Income (Loss)       (13.9) (13.9)
Balances at end of period at Mar. 31, 2025 [2] $ 1.0 (157.9) 405.3 (52.4) 196.0
Balances at end of period (in shares) at Mar. 31, 2025 [2] 85,587,885        
Balances at beginning of period at Dec. 31, 2024 $ 1.0 (156.6) 402.9 (38.5) $ 208.8
Balances at beginning of period (in shares) at Dec. 31, 2024 84,810,418       84,810,418
Increase (Decrease) in Stockholders' Deficit          
Net Income (Loss)         $ (31.7)
Balances at end of period at Jun. 30, 2025 [2] $ 1.0 (157.9) 408.0 (70.2) $ 180.9
Balances at end of period (in shares) at Jun. 30, 2025 85,724,788 [2]       85,724,788
Balances at beginning of period at Mar. 31, 2025 [2] $ 1.0 (157.9) 405.3 (52.4) $ 196.0
Balances at beginning of period (in shares) at Mar. 31, 2025 [2] 85,587,885        
Increase (Decrease) in Stockholders' Deficit          
Stock-based compensation     2.7   2.7
Issuance of restricted stock, net (in shares) 148,575        
Purchase of shares (in shares) (11,672)        
Net Income (Loss)       (17.8) (17.8)
Balances at end of period at Jun. 30, 2025 [2] $ 1.0 $ (157.9) $ 408.0 $ (70.2) $ 180.9
Balances at end of period (in shares) at Jun. 30, 2025 85,724,788 [2]       85,724,788
[1] Included in outstanding shares as of March 31, 2024 and June 30, 2024 are 1,482,690 and 2,726,560, respectively, of non-vested shares of restricted stock awards granted to employees and directors.
[2] Included in outstanding shares as of March 31, 2025 and June 30, 2025, are 2,939,868 and 2,834,105, respectively, of non-vested shares of restricted stock awards granted to employees and directors.